Although ET patients had significantly lower numbers of CD19-positive B cells and naïve B cells when compared to healthy adults, ET patients with CALR and JAK2 mutations had statistically higher numbers of CD69-positive and CD86-positive activated B cells (Figure 3A and 3C, respectively). This evidence concerns the gene JAK2 and essential thrombocythemia.